Subsidiaries of KPS
Full menu
About KPS
Investor Relations
Subsidiaries of KPS
algok bio
Welcome
We're an experienced and talented group of entrepreneurs and scientists with a groundbreaking idea that we hope will be better tomorrow.
Overview
| Date of foundation | 2020.09 |
|---|---|
| Name of CEO(s) | Sung Chul Kim |
| Paid-in capital | USD 2,566,667 |
| Main Business | Targeted therapy for non-small cell lung cancer(NSCLC) (AGK-102: anti-TM4SF4 monoclonal antibody 백금계저항성 난소암 적용 엽산수용체알파(Folate Receptor alpha, FRα) 표적항암제 (Idetrexed(이데트렉세드) |
| Tel | +1-425-598-2107 |
| Address | 320 120th Ave. NE, Suite 208 Bellevue, WA 98005, USA |
AGK-102:
Anti-TM4SF4
monoclonal antibody
| Licensed Technology |
· Invented by Korea Atomic Energy Research Institute in Korea · Algok obtained an exclusive global right for all uses of novel TM4SF4 monoclonal antibody for cancer therapeutics · Sponsored research is planned for 3 years |
|---|---|
| MoA |
· First-in-class · TM4SM4 as a novel cancer stem cell biomarker related to resistance of radiotherapy · Anti-TM4SM4 treatment suppresses tumors by down-regulation of OPN and blocking IGF1R signaling |
| Target Indications |
· NSCLC, pancreatic, liver, blood cancer expressing TM4SM4 |
| Development Stage |
· Initiation of preclinical development in 2H 2022 |
| Intellectual Properties |
· 3 PCT filed including the composition of matter of novel antibody sequences |
| Publications |
· 2 Published in OncoTarget in 2015 and 2017 |
Background
Cancer stem cell as root of tumor recurrence
CSC is characterized by self‐renewal, metastasis, apoptosis, heterogeneity, immune resistance, and radio/chemo resistance.
Mechanism of
Action
TM4SF4: a novel anti-tumor target in radio-resistant cancer cells
TM4SF4 is highly expressed in radio-resistant lung adenocarcinoma cells.
Tumorigenic activity of TM4SF4 in lung adenocarcinoma xenograft was completely suppressed by anti-TM4SF4 antibody treatment.
